If I had $10,000 to invest in an S&P/ASX 200 Index (ASX: XJO) share today, one company would be near the top of my shopping list.
That company is Sigma Healthcare Ltd (ASX: SIG).
The business behind Chemist Warehouse has become one of Australia's largest healthcare companies, and I think there's still plenty of growth ahead.

Image source: Getty Images
More than just Chemist Warehouse
Most investors probably associate Sigma with Chemist Warehouse's bright yellow stores and heavily discounted products.
However, the company's pharmaceutical distribution network is another important part of the investment case.
During FY26, Sigma distributed more than 579 million units to over 2,500 pharmacy customers across Australia. And after handling 6.5% more products than a year earlier, its distribution cost per unit declined.
I think that demonstrates the benefits of having such a large operation. As volumes increase, Sigma can spread its operating costs across more products, potentially improving profitability.
The company is also streamlining its distribution centres and eliminating duplicated transport costs following the Chemist Warehouse merger.
Management has already delivered $32.6 million in annual integration benefits and is targeting $100 million annually by FY29.
That's a meaningful opportunity to grow its net profit after tax without relying entirely on opening more pharmacies.
Its online business is another growth driver
Something else that has caught my attention is the performance of Chemist Warehouse's online operations.
During FY26, online revenue increased 16%, supported by a 22% increase in customer orders.
But what I found more interesting was how customers are choosing to receive their purchases. More than 80% of online sales are now fulfilled through Click & Collect.
I think this highlights another advantage of Chemist Warehouse's enormous physical presence.
Customers can browse products online, place orders, and conveniently collect them from their local pharmacy. And once they're in-store, there's always the possibility they'll purchase something else.
With Sigma continuing to invest in personalisation, search, and online fulfilment, I think its digital operations could become an increasingly important driver of growth.
The growth continues
Perhaps the strongest reason I would buy this ASX 200 share is that its growth momentum remains impressive.
In October, management revealed that Australian Chemist Warehouse branded stores had increased sales by 12.1% since the start of FY27.
Even more encouragingly, like-for-like sales increased 9.8%. This suggests the company is continuing to attract more customer spending from its existing stores, rather than relying solely on expansion.
International sales were also up 30.2% in the first quarter.
And with new stores planned across Australia and overseas, I think Sigma has plenty of opportunities to maintain this momentum.
Foolish takeaway
I think Sigma offers an attractive combination of established market positions and long-term growth potential.
Its pharmacy network is already enormous, but management is finding ways to generate more sales while improving efficiency across the business.
Of course, there's a risk that investors could pay too much for that growth, and the company still has plenty of work ahead integrating its operations.
Nevertheless, if I were investing $10,000 in a single ASX 200 share with a 10-year horizon, I would be happy to back Sigma.